- Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
May 11, 2026
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Agilon Health (AGL) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agilon Health is one of 888 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AGL's full-year earnings has moved 47.5% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that AGL has returned about 215% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -8.2% on a year-to-date basis. This shows that Agilon Health is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Amarin (AMRN). The stock is up 7.9% year-to-date.
The consensus estimate for Amarin's current year EPS has increased 12.1% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Agilon Health belongs to the Medical Services industry, a group that includes 63 individual companies and currently sits at #98 in the Zacks Industry Rank. Stocks in this group have lost about 11% so far this year, so AGL is performing better this group in terms of year-to-date returns.
In contrast, Amarin falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 432 stocks and is ranked #142. Since the beginning of the year, the industry has moved -1.8%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Agilon Health and Amarin as they could maintain their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Story Continues
Agilon Health, Inc. (AGL) : Free Stock Analysis Report
Amarin Corporation PLC (AMRN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Agilon (AGL) Is Attractively Priced Despite Fast-paced Momentum
May 11, 2026
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.
Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth potential fails to justify their swelled-up valuation. In that phase, investors find themselves invested in shares that have limited to no upside or even a downside. So, betting on a stock just by looking at the traditional momentum parameters could be risky at times.
A safer approach could be investing in bargain stocks with recent price momentum. While the Zacks Momentum Style Score (part of the Zacks Style Scores system) helps identify great momentum stocks by paying close attention to trends in a stock's price or earnings, our 'Fast-Paced Momentum at a Bargain' screen comes handy in spotting fast-moving stocks that are still attractively priced.
There are several stocks that currently pass through the screen and Agilon Health (AGL) is one of them. Here are the key reasons why this stock is a great candidate.
A dash of recent price momentum reflects growing interest of investors in a stock. With a four-week price change of 185.1%, the stock of this senior-focused health care company is certainly well-positioned in this regard.
While any stock can see a spike in price for a short period, it takes a real momentum player to deliver positive returns for a longer time frame. AGL meets this criterion too, as the stock gained 500.9% over the past 12 weeks.
Moreover, the momentum for AGL is fast paced, as the stock currently has a beta of 2.29. This indicates that the stock moves 129% higher than the market in either direction.
Given this price performance, it is no surprise that AGL has a Momentum Score of A, which indicates that this is the right time to enter the stock to take advantage of the momentum with the highest probability of success.
In addition to a favorable Momentum Score, an upward trend in earnings estimate revisions has helped AGL earn a Zacks Rank #2 (Buy). Our research shows that the momentum-effect is quite strong among Zacks Rank #1 and #2 stocks. That's because as covering analysts raise their earnings estimates for a stock, more and more investors take an interest in it, helping its price race to keep up. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Story Continues
Most importantly, despite possessing fast-paced momentum features, AGL is trading at a reasonable valuation. In terms of Price-to-Sales ratio, which is considered as one of the best valuation metrics, the stock looks quite cheap now. AGL is currently trading at 0.16 times its sales. In other words, investors need to pay only 16 cents for each dollar of sales.
So, AGL appears to have plenty of room to run, and that too at a fast pace.
In addition to AGL, there are several other stocks that currently pass through our 'Fast-Paced Momentum at a Bargain' screen. You may consider investing in them and start looking for the newest stocks that fit these criteria.
This is not the only screen that could help you find your next winning stock pick. Based on your personal investing style, you may choose from over 45 Zacks Premium Screens that are strategically created to beat the market.
However, keep in mind that the key to a successful stock-picking strategy is to ensure that it produced profitable results in the past. You could easily do that with the help of the Zacks Research Wizard. In addition to allowing you to backtest the effectiveness of your strategy, the program comes loaded with some of our most successful stock-picking strategies.
Click here to sign up for a free trial to the Research Wizard today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agilon Health, Inc. (AGL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?
May 11, 2026 · zacks.com
Here is how Agilon Health (AGL) and Amarin (AMRN) have performed compared to their sector so far this year.
- Agilon (AGL) Is Attractively Priced Despite Fast-paced Momentum
May 11, 2026 · zacks.com
Agilon (AGL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
- Exploring 3 Top Undervalued Small Caps With Insider Action Across Regions
May 8, 2026
Over the last 7 days, the United States market has experienced a rise of 3.2%, contributing to a 31% increase over the past year, with earnings forecasted to grow by 16% annually. In this dynamic environment, identifying small-cap stocks that are potentially undervalued and exhibit insider activity can offer intriguing opportunities for investors seeking value in diverse regions.
Top 10 Undervalued Small Caps With Insider Buying In The United States
Name PE PS Discount to Fair Value Value Rating First United 9.7x 2.8x 46.65% ★★★★★☆ Financial Institutions 9.0x 2.9x 31.34% ★★★★★☆ Metropolitan Bank Holding 13.0x 3.7x 39.83% ★★★★☆☆ First Bancorp 9.0x 3.4x 43.49% ★★★★☆☆ PCB Bancorp 8.9x 3.1x 16.33% ★★★★☆☆ Aldeyra Therapeutics NA NA 45.82% ★★★★☆☆ Bank of Marin Bancorp NA 11.7x 33.78% ★★★☆☆☆ Bank of the James Financial Group 9.6x 2.1x 39.84% ★★★☆☆☆ New Peoples Bankshares 9.9x 2.4x 21.02% ★★★☆☆☆ CEVA NA 8.6x -109.11% ★★★☆☆☆
Click here to see the full list of 68 stocks from our Undervalued US Small Caps With Insider Buying screener.
Below we spotlight a couple of our favorites from our exclusive screener.
CEVA
Simply Wall St Value Rating: ★★★☆☆☆
Overview: CEVA is a technology company specializing in the licensing of intellectual property, with operations focused on providing semiconductor solutions and a market cap of approximately $0.84 billion.
Operations: CEVA generates revenue primarily through the licensing of intellectual property, with a recent revenue figure of $109.60 million. The company's cost structure includes significant research and development expenses, which reached $74.83 million in the latest period. Gross profit margin has shown variability, with a recent value of 87.08%.
PE: -88.3x
CEVA stands out in the small-cap category, with its innovative RealSpace audio technology recently selected by Lenovo for a new headset, highlighting industry recognition. Despite reporting a net loss of US$10.64 million for 2025, revenue increased to US$109.6 million from the previous year. The company has not diluted shares over the past year and shows insider confidence through share purchases completed under a long-term buyback plan announced in 2014. CEVA's advancements in UWB and 5G-NTN technologies position it well for future growth opportunities across various sectors.
Unlock comprehensive insights into our analysis of CEVA stock in this valuation report. Gain insights into CEVA's past trends and performance with our Past report.CEVA Ownership Breakdown as at May 2026
Financial Institutions
Simply Wall St Value Rating: ★★★★★☆
Overview: Financial Institutions operates primarily in the banking sector with additional income from investment advisory services, and it has a market capitalization of approximately $0.31 billion.
Story Continues
Operations: The company's primary revenue stream is derived from its banking operations, contributing $233.33 million, while investment advisory income adds $11.86 million. Operating expenses are significant, with general and administrative expenses consistently forming a large portion of these costs. Over recent periods, the net income margin has shown variability but was recorded at 32.38% in the latest available data point for March 2026.
PE: 9.0x
Financial Institutions, Inc. has shown promising financial performance with net interest income rising to US$51.99 million in Q1 2026 from US$46.86 million a year prior, and net income reaching US$20.99 million compared to US$16.88 million previously. Insider confidence is evident as they have been actively purchasing shares, while the company completed a buyback of 500,066 shares for $15.91 million by March 31, 2026. The recent dividend increase reflects a stable cash flow position and commitment to shareholder returns amidst board changes as Donald K. Boswell steps down after nine years of service to pursue other interests.
Navigate through the intricacies of Financial Institutions with our comprehensive valuation report here. Learn about Financial Institutions' historical performance.FISI Share price vs Value as at May 2026
agilon health
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Agilon Health is a healthcare company that partners with primary care physicians to provide value-based care for seniors, with a market cap of approximately $7.58 billion.
Operations: AGL generates revenue primarily through its healthcare services, with recent figures showing $5.82 billion in revenue for the quarter ending March 31, 2026. The company's cost structure is heavily influenced by COGS, which was $5.97 billion during the same period, resulting in a gross profit margin of -2.50%. Operating expenses are significant as well, with general and administrative expenses accounting for a substantial portion at $215.15 million in the latest quarter.
PE: -2.7x
Agilon health, a healthcare company with a focus on physician-led value-based care, has seen significant changes recently. They reported Q1 2026 revenue of US$1.42 billion, down from US$1.53 billion the previous year, yet net income rose to US$48.92 million from US$12.11 million. Insider confidence was evident in recent share purchases by executives in early 2026, suggesting belief in the company's strategy despite its current unprofitability and reliance on higher-risk funding sources like external borrowing. A reverse stock split effective March 31 aimed to enhance marketability and meet NYSE listing requirements while new CEO Tim O’Rourke's leadership is expected to leverage his extensive healthcare experience for future growth amid ongoing industry demand for innovative care solutions.
Get an in-depth perspective on agilon health's performance by reading our valuation report here. Assess agilon health's past performance with our detailed historical performance reports.AGL Ownership Breakdown as at May 2026
Next Steps
Access the full spectrum of 68 Undervalued US Small Caps With Insider Buying by clicking on this link. Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks. Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Ready For A Different Approach?
Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CEVAFISI and AGL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
May 7, 2026
Shares of Agilon Health cratered in 2025, driven by financial underperformance and a guidance suspension.
Continue Reading
- Thursday Sector Leaders: Precious Metals, Hospital & Medical Practitioners
May 7, 2026
In trading on Thursday, precious metals shares were relative leaders, up on the day by about 4.4%. Leading the group were shares of Endeavour Silver, up about 18.8% and shares of B2Gold up about 16.2% on the day.
Also showing relative strength are hospital & medical practitioners shares, up on the day by about 3.6% as a group, led by Agilon Health, trading higher by about 96.3% and Clover Health Investments, trading higher by about 7.3% on Thursday.
VIDEO: Thursday Sector Leaders: Precious Metals, Hospital & Medical Practitioners
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.
May 7, 2026 · barrons.com
Shares of Agilon Health cratered in 2025, driven by financial underperformance and a guidance suspension.
- Agilon Health Operational Initiatives Begin Showing Results
May 7, 2026 · benzinga.com
Agilon Health Inc. (NYSE:AGL) shares are soaring on Thursday as the company recently announced an increase in its full-year 2026 guidance. The company operates and manages a network of independent physicians.
- agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
May 6, 2026 · seekingalpha.com
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
